1. Type of calcineurin inhibitor and long-term outcomes following liver transplantation in patients with primary biliary cholangitis – an ELTR study
- Author
-
Maria C. van Hooff, Rozanne C. de Veer, Vincent Karam, Rene Adam, Pavel Taimr, Wojciech G. Polak, Hasina Pashtoun, Sarwa Darwish Murad, Christophe Corpechot, Darius Mirza, Michael Heneghan, Peter Lodge, Gabriel C. Oniscu, Douglas Thorburn, Michael Allison, Herold J. Metselaar, Caroline M. den Hoed, Adriaan J. van der Meer, Gabriel Oniscu, Johann Pratschke, Derek Manas, William Bennet, Pal-Dag Line, Emir Hot, Krzysztof Zieniewicz, Bo Goran Ericzon, Jiri Fronek, Jurgen L. Klempnauer, Allan Rasmussen, Renato Romagnoli, Petr Nemec, Arno Nordin, Andreas Paul, Paolo De Simone, R.J. Porte, Gabriela Berlakovich, Daniel Cherqui, Jacques Pirenne, Etienne Sokal, Giorgio Rossi, Daniel Candinas, Philippe Bachellier, Oleg Rummo, Karim Boudjema, Anna Mrzljak, Olivier Soubrane, Herold Metselaar, Stefan Schneeberger, Francis Navarro, Thierry Berney, Christophe Duvoux, Michele Colledan, Luciano De Carlis, Olivier Boillot, Jean Hardwigsen, Francois Rene Pruvot, Bertrand Suc, Marco Vivarelli, Pierre Alain Clavien, Hauke Lang, Maciej Kosieradzki, Frederik Berrevoet, Bruno Heyd, Matteo Cescon, Laurence Chiche, Eberhard Kochs, Umberto Baccarani, Olivier Detry, Michael Bartels, Massimo Rossi, Olivier Scatton, Vasileios Papanikolaou, Ian Alwayn, Peter Schemmer, N. Senninger, Christian Ducerf, Fabrizio Di Benedetto, Giuseppe Tisone, Silvio Nadalin, Zoltan Mathe, Marija Ribnikar, Utz Settmacher, Thomas Becker, Nuno Silva, Jorge Daniel, Irinel Popescu, Valerio Lucidi, Wolf O. Bechstein, Thomas Decaens, Jean Gugenheim, Salvatore Gruttadauria, Frausto Zamboni, Murat Zeytunlu, Jorg C. Kalff, Toomas Vali, Yaman Tokat, Ernst Klar, Julius Janek, Murat Kilic, Krum Katzarov, Lutz Fisher, Emmanuel Buc, Marco Castagneto, Tarkan Unek, Lubomir Spassov, Dirk Stippel, Christiane Bruns, Hans Schlitt, Ephrem Salame, Piotr Kalicinski, and Koray Acarli
- Subjects
Calcineurin inhibitors ,Graft survival ,Liver Transplantation ,Primary Biliary Cholangitis ,Survival ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Background & Aims: Tacrolimus has been associated with recurrence of primary biliary cholangitis (PBC) after liver transplantation (LT), which in turn may reduce survival. This study aimed to assess the association between the type of calcineurin inhibitor used and long-term outcomes following LT in patients with PBC. Methods: Survival analyses were used to assess the association between immunosuppressive drugs and graft or patient survival among adult patients with PBC in the European Liver Transplant Registry. Patients who received a donation after brain death graft between 1990 and 2021 with at least 1 year of event-free follow-up were included. Results: In total, 3,175 patients with PBC were followed for a median duration of 11.4 years (IQR 5.9–17.9) after LT. Tacrolimus (Tac) was registered in 2,056 (64.8%) and cyclosporin in 819 (25.8%) patients. Following adjustment for recipient age, recipient sex, donor age, and year of LT, Tac was not associated with higher risk of graft loss (adjusted hazard ratio [aHR] 1.07, 95% CI 0.92-1.25, p = 0.402) or death (aHR 1.06, 95% CI 0.90-1.24, p = 0.473) over cyclosporin. In this model, maintenance mycophenolate mofetil (MMF) was associated with a lower risk of graft loss (aHR 0.72, 95% CI 0.60-0.87, p
- Published
- 2024
- Full Text
- View/download PDF